

Papua New Guinea

Support for Vaccine: Measles Rubella This Decision Letter sets out the Programme Terms of a Programme.

Country:	Papua New G	uinea						
Vaccine gran	t number:			•	•		PNG-09a-X, 18-	
Date of Decis	ion Letter:	30/09	/2019					
Date of the Pa	artnership Fr	amework Agreeme	ent (PF	A) : :	29/11/2013			
Programme to	itle:	New Vaccine Support (NVS), Measles Rubella, SD Routine - Strat 1						
Vaccine type:		Measles Rubella						
	•			vaccine:				
	•	•						
Programme E	Budget (indica	ative):² (subje	ect to the	e terms of the	PFA, if applic	cable)		
		2015-2019		2020		Total ²		
Programme B	udget (US\$)	2	77,211		61,500		338,711	
Vaccine intro	duction gran	t:						
Γ								
-	Voor			Amauni	· (IIC¢)			
	2015			Amount	122,816			
- Г		Net Disbursement						
Disburser		•		t (US\$)				
	14 July	, 2014		122,816				
Product swite	ch grant: Not	applicable						
Indicative An	nual Amount	s:³ (subje	ect to the	e terms of the	PFA, if applic	cable)		
	ed with Gavi							
		201	5-2019		2020		2021	
purchase Number of v	ed with Gavi funds accine doses				206,700		2021	
purchase Number of v	ed with Gavi funds		5-2019 77,211				2021	
purchase Number of v	ed with Gavi funds accine doses nounts (US\$) agency:		77,211	II release its co	206,700 61,500	ayments ea	-	
Number of v	ed with Gavi funds accine doses nounts (US\$) agency:	2 UNICEF. The Cou	77,211	II release its co	206,700 61,500	ayments ea	-	
	Vaccine gran Date of Decis Date of the Pa Programme t Vaccine type Requested programme E Programme E Programme B Vaccine intro	Vaccine grant number: Date of Decision Letter: Date of the Partnership From Programme title: Vaccine type: Requested product preser Measles Rubella, 10 dose(some programme Duration:1) Programme Budget (indication granme Budget (US\$)) Vaccine introduction granme Programme Budget (US\$) Vaccine introduction granme Programme Production granme Product granme Production granme Product granme	Vaccine grant number: Date of Decision Letter: Date of the Partnership Framework Agreemed Programme title: New Vaccine Suppower Waccine type: Measles Rubella Requested product presentation and formulal Measles Rubella, 10 dose(s) per vial, LYOPHIL Programme Duration: Programme Budget (indicative): 2015-2020 Programme Budget (indicative): 2015-2019 Programme Budget (US\$) Vaccine introduction grant: Appower Grant Number 2015 Appower Grant Number 2015 Net Disbursement date 14 July, 2014 Product switch grant: Not applicable	Vaccine grant number: Date of Decision Letter: Date of the Partnership Framework Agreement (PFA) Programme title: New Vaccine Support (NVS) Vaccine type: Measles Rubella Requested product presentation and formulation of Measles Rubella, 10 dose(s) per vial, LYOPHILISED Programme Duration: 2015-2020 Programme Budget (indicative): 2015-2019 Programme Budget (US\$) 277,211 Vaccine introduction grant: Approval Year Grant Number 2015 15-PNG-08e-Y Net Disbursement Disbursement date Amount 14 July, 2014 Product switch grant: Not applicable Indicative Annual Amounts: (subject to the Subject to the Su	Vaccine grant number: Date of Decision Letter: Date of the Partnership Framework Agreement (PFA): Programme title: New Vaccine Support (NVS), Measles Reversed product presentation and formulation of vaccine: Measles Rubella Requested product presentation and formulation of vaccine: Measles Rubella, 10 dose(s) per vial, LYOPHILISED Programme Duration: 2015-2020 Programme Budget (indicative): (subject to the terms of the 2015-2019 Programme Budget (US\$) 277,211 Vaccine introduction grant: Approval Year Grant Number Amount 2015 15-PNG-08e-Y Net Disbursement Disbursement date Amount (US\$) 14 July, 2014 122,816 Product switch grant: Not applicable Indicative Annual Amounts: (subject to the terms of the	Vaccine grant number: 15-PNG-08e-Y, 15-PNG-09a-X, 16-PNG-09a-X, 19-PNG-09a-X, 19-PNG-09a-X, 20-PNG-09a-X, 20-PNG-09a-X, 19-PNG-09a-X, 20-PNG-09a-X, 20-PNG-09a-X, 19-PNG-09a-X, 20-PNG-09a-X, 20-PNG-09a-X, 20-PNG-09a-X, 19-PNG-09a-X, 20-PNG-09a-X, 20-PNG-09a-X, 19-PNG-09a-X, 19-PNG-09a-X, 16-PNG-09a-X, 19-PNG-09a-X, 16-PNG-09a-X, 19-PNG-09a-X, 16-PNG-09a-X, 16-PNG-	Vaccine grant number: 15-PNG-08e-Y, 15-PNG-09a-X, 16-PNG-09a-X, 17-PNG-09a-X, 19-PNG-09a-X, 20-PNG-09a-X, 17-PNG-09a-X, 20-PNG-09a-X Date of Decision Letter: 30/09/2019 Date of the Partnership Framework Agreement (PFA): Programme title: New Vaccine Support (NVS), Measles Rubella, SD Routine - Strate Vaccine type: Measles Rubella Requested product presentation and formulation of vaccine: Measles Rubella, 10 dose(s) per vial, LYOPHILISED Programme Duration: 2015-2020 Programme Budget (indicative): (subject to the terms of the PFA, if applicable) Vaccine introduction grant: Approval Year Grant Number Amount (US\$) 2015 15-PNG-08e-Y 122,816 Net Disbursement Disbursement date Amount (US\$) 14 July, 2014 122,816 Product switch grant: Not applicable Indicative Annual Amounts: (subject to the terms of the PFA, if applicable)	

 $^{^{\}rm 1}$ This is the entire duration of the programme. $^{\rm 2}$ This is the total amount endorsed by Gavi for the entire duration of the programme. $^{\rm 3}$ This is the amount that Gavi has approved.



16. Operational support for campaigns: Net disbursement of US\$1,599,882 (2014 / 2017 / 2018)

17. Additional Reporting Requirements:

		Due dates
	or the annual procurement of vaccines, Country shall submit the ormation each year:	
•	Vaccine stock levels including buffer stock, by end of March;	31 March 2020
•	Number of children to be vaccinated, wastage rates, any proposed changes in product, presentation or use, or minimum co-financing levels and vaccines received, by mid-May.	15 May 2020
•	Countries shall report the actual switch date in the first renewal request following the actual implementation.	
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.		To be agreed with Gavi Secretariat

18. Financial clarifications: Not applicable

19. Other conditions:

Country has presented an official request to Gavi to switch from measles vaccine to measles-rubella vaccine for the routine measles second dose with country funding for the equivalent cost of the rublella component. As such, country will make the required payments to UNICEF SD as indicated in the table below.

	2020
Number of doses of vaccines for Measles Second Dose approved by Gavi.	206,700
Amount for vaccines approved by Gavi in US\$ (excluding freight and insurance).	61,500
Number of doses of Measles-Rubella vaccine that can be purchased with Gavi support.	90,431
Number of doses of Measles-Rubella vaccine to be funded by country.	116,269
Amount for Measles-Rubella vaccines to be funded by country (excluding freight and	76,272

Signed by,

On behalf of Gavi

Thabani Maphosa

Managing Director, Country Programmes

30 September 2019